JPMorgan Chase & Co. Has $1.11 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

JPMorgan Chase & Co. boosted its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 94.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 83,826 shares of the company's stock after purchasing an additional 40,721 shares during the quarter. JPMorgan Chase & Co.'s holdings in Takeda Pharmaceutical were worth $1,110,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Versant Capital Management Inc acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at $26,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Takeda Pharmaceutical during the third quarter valued at about $40,000. Farther Finance Advisors LLC boosted its position in shares of Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. acquired a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at about $52,000. Finally, Cromwell Holdings LLC bought a new stake in Takeda Pharmaceutical in the 4th quarter valued at about $61,000. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $15.03 on Monday. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The firm has a fifty day simple moving average of $14.72 and a two-hundred day simple moving average of $13.93. Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.37. The firm has a market capitalization of $47.82 billion, a PE ratio of 37.58, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.